SCHEMBL938602

SCHEMBL938602

OC[C](F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8522991 0.71
SCHEMBL15938 0.71
SCHEMBL11403945 0.67
SCHEMBL8532418 0.67
SCHEMBL1591041 0.67
SCHEMBL5695732 0.64
Water SCHEMBL250510 0.63 TSHR (0.43)
Methane SCHEMBL10519735 0.63 TSHR (0.43)
SCHEMBL11334969 0.63
SCHEMBL3628469 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4392032-A1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME Arena Pharmaceuticals, Inc. (US) 2024-07-03 EP claimed
US-20240197888-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-06-20 US claimed
US-20240174643-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2024-05-30 US claimed
EP-4355741-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS Biotheryx, Inc. (US) 2024-04-24 EP claimed
WO-2023178130-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-09-21 WO claimed
CN-116710450-A Pyrrolo [3,2-b ] pyridine derivatives for the treatment of cGAS-related disorders 诺华股份有限公司 2023-09-05 CN claimed
CN-116635382-A Indole derivatives useful for treating cGAS-related disorders 诺华股份有限公司 2023-08-22 CN claimed
WO-2023026185-A1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME ARENA PHARMACEUTICALS, INC. (US) 2023-03-02 WO claimed
WO-2022266248-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2022-12-22 WO claimed
EP-3442945-B1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2020-07-08 EP claimed
US-20170304292-A1 Tetrahydroisoquinoline Derivatives UCB BIOPHARMA SPRL (BE) 2017-10-26 US claimed
CN-102712619-B 5-hydroxy pyrimidine-4-carboxamides derivatives DAIICHI SANKYO Co.,Ltd. (JP) 2015-11-25 CN claimed
EP-2492266-B1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP claimed
US-8785462-B2 5-hydroxypyrimidine-4-carboxamide derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-07-22 US claimed
US-20120220609-A1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-08-30 US claimed
EP-2492266-A1 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-08-29 EP claimed
WO-2002021216-A9 POLYMERS AND PHOTORESIST COMPOSITIONS COMPRISING ELECTRONEGATIVE GROUPS SHIPLEY CO LLC (US) 2003-04-03 WO claimed
US-20020058199-A1 Novel polymers and photoresist compositions comprising electronegative groups SHIPLEY COMPANY, L.L.C. 2002-05-16 US claimed
WO-2002021216-A2 POLYMERS AND PHOTORESIST COMPOSITIONS COMPRISING ELECTRONEGATIVE GROUPS SHIPLEY COMPANY, L.L.C. (US) 2002-03-14 WO claimed
US-5492792-A OPTICAL CARD OR DISKS; EXCELLENT LIGHT SENSITIVITY WITHIN NEAR INFRARED REGION AND HEAT RESISTANCE; STORE INFORMATIONSAT HIGH DENSITY CANON KABUSHIKI KAISHA (JP) 1996-02-20 US claimed